Recro Pharma is a contract development and manufacturing organization, solving formulation and manufacturing challenges primarily in small molecule therapeutic development. Co. utilizes its formulation and development knowledge to develop and manufacture pharmaceutical products using proprietary delivery technologies and know-how for partners who develop and commercialize or plan to commercialize these products. Co. has launched its clinical trials support services capabilities, which includes preparation of clinical trial supplies, as well as services dedicated to the development and Good Manufacturing Practices, of high-potency products. The REPH average annual return since 2014 is shown above.
The Average Annual Return on the REPH average annual return since 2014 page and across the coverage universe of our site,
is a measure of the annualized return over the past ten years (or specified start date) for a given investment
(up to the end of prior trading session recorded). Arguably, choosing ten years for a measurement
period is on the one hand completely arbitrary, but on the other hand provides a sufficiently long window
to capture long-term trends.
Thus, researching Average Annual Returns is good practice for investors — whether REPH average annual return since 2014 or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's annualized return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the REPH average annual return calculation with any dividends reinvested as applicable (on ex-dates).
|
Free REPH Email Alerts:
Video: Don't Forget Dividends in Average Annual Return!
